Cost-minimization analysis of panitumumab compared with cetuximab for first-line treatment of patients with wild-type RAS metastatic colorectal cancer

References

• National Cancer Institute (NCI). Cancer stat fact sheets: cancer of the colon and rectum. Bethesda, MD: National Cancer Institute, 2014. http://seer.cancer.gov/statfacts/html/colorect.html. Accessed July 14, 2014
   Google Scholar
• American Cancer Society. Cancer facts & figures 2015. Atlanta, GA: American Cancer Society, 2015. http://www.cancer.org/acs/groups/content/@editorial/documents/document/acspc-044552.pdf. Accessed March 12, 2015
   Google Scholar
• National Comprehensive Cancer Network (NCCN). NCCN practice guidelines in oncology: colon cancer. Fort Washington, PA: National Comprehensive Cancer Network, 2014. http://www.nccn.org/professionals/physician_gls/pdf/colon.pdf. Accessed February 28, 2014
   Google Scholar
• National Comprehensive Cancer Network (NCCN). NCCN practice guidelines in oncology: rectal cancer. Fort Washington, PA: NationalComprehensive Cancer Network, 2014. http://www.nccn.org/professionals/physician_gls/pdf/rectal.pdf. Accessed February 28, 2014
   Google Scholar
• Van Cutsem E, Köhne CH, Hitre E, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009;360:1408-17
   PubMed Web of Science ®Google Scholar
• Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004;351:337-45
   PubMed Web of Science ®Google Scholar
• Amado RG, Wolf M, Peeters M, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008;26:1626-34
   PubMed Web of Science ®Google Scholar
• Karapetis CS, Khambata-Ford S, Jonker DJ, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008;359:1757-65
   PubMed Web of Science ®Google Scholar
• Douillard JY, Siena S, Cassidy J, et al. Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer. Ann Oncol 2014;25:1346-55
   PubMed Web of Science ®Google Scholar
• Douillard JY, Oliner KS, Siena S, et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med 2013;369:1023-34
   PubMed Web of Science ®Google Scholar
• Schwartzberg LS, Rivera F, Karthaus M, et al. PEAK: a randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal cancer. J Clin Oncol 2014;32:2240-7
   PubMed Web of Science ®Google Scholar
• Stintzing S, Jung A, Rossius L, et al. Mutations within the EGFR signaling pathway: Influence on efficacy in FIRE-3—A randomized phase III study of FOLFIRI plus cetuximab or bevacizumab as first-line treatment for wild-type (WT) KRAS (exon 2) metastatic colorectal cancer (mCRC) patients. J Clin Oncol 2014;32(3 Suppl):abstr 445
   Google Scholar
• Tejpar S, Lenz HJ, Köhne CH. Effect of KRAS and NRAS mutations on treatment outcomes in patients with metastatic colorectal cancer (mCRC) treated first-line with cetuximab plus FOLFOX4: new results from the OPUS study. J Clin Oncol 2014;32(3 Suppl):Abstract LBA444
   Google Scholar
• Brodowicz T, Vrbanec D, Kaczirek K, et al. FOLFOX4 plus cetuximab administered weekly or every two weeks in first-line treatment of patients with KRAS and NRAS wild-type metastatic colorectal cancer. J Clin Oncol 2014;32(3 Suppl):abstr LBA391^
   Google Scholar
• Price TJ, Peeters M, Kim TW, et al. Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study. Lancet Oncol 2014;15:569-79
   PubMed Web of Science ®Google Scholar
• Panitumumab (Vectibix) prescribing information. 2014. http://pi.amgen.com/united_states/vectibix/vectibix_pi.pdf. Accessed July 14, 2014
   Google Scholar
• Cetuximab (Erbitux) prescribing information. 2013. Available at: http://packageinserts.bms.com/pi/pi_erbitux.pdf. Accessed July 14, 2014
   Google Scholar
• Latimer N. NICE DSU Technical Support Document 14: undertaking survival analysis for economic evaluations alongside clinical trials - extrapolation with patient-level data. Sheffield, UK: Decision Support Unit, 2011. http://www.nicedsu.org.uk/NICE%20DSU%20TSD%20Survival%20analysis.updated%20March%202013.v2.pdf. Accessed December 10, 2014
   Google Scholar
• Centers for Medicare and Medicaid Services (CMS). Payment allowance limits for Medicare Part B drugs. Baltimore, MD: Centers for Medicare and Medicaid Services, 2014
   Google Scholar
• Micromedex. Red Book Online. Accessed through Micromedex 2.0. Greenwood Village, CO: Thomson Reuters, 2014. www.micromedexsolutions.com. Accessed February 20, 2014
   Google Scholar
• NHANES. Centers for Disease Control and Prevention (CDC). National Center for Health Statistics (NCHS). National Health and Nutrition Examination Survey Data. Hyattsville, MD: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, 2011
   Google Scholar
• Oxaliplatin (Eloxatin) prescribing information. 2014. http://products.sanofi.us/eloxatin/eloxatin.pdf. Accessed July 14, 2014
   Google Scholar
• Irinotecan (Camptosar) prescribing information. 2012. http://labeling.pfizer.com/ShowLabeling.aspx?id=533. Accessed July 14, 2014
   Google Scholar
• Leucovorin calcium prescribing information. 2014. http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=886aeb54-2abf-4ca5-8a0d-4d881b2e46a9. Accessed July 14, 2014
   Google Scholar
• Centers for Medicare and Medicaid Services (CMS). CMS final 2014 National Limit Amount for CPT code 81275. Physician fee schedule search. Baltimore, MD: Centers for Medicare and Medicaid Services, 2014. http://www.cms.gov/apps/physician-fee-schedule. Accessed July 3, Baltimore, MD: Centers for Medicare and Medicaid Services, 2014
   Google Scholar
• Centers for Medicare and Medicaid Services (CMS). FOLFOX/FOLFIRI and CMS costs. Baltimore, MD: Centers for Medicare and Medicaid Services, 2014
   Google Scholar
• Centers for Medicare and Medicaid Services (CMS). CPT code 96413. Physician fee schedule search. Baltimore, MD: Centers for Medicare and Medicaid Services, 2014. http://www.cms.gov/apps/physician-fee-schedule. Accessed July 3, 2014
   Google Scholar
• Centers for Medicare and Medicaid Services (CMS). CPT Code 96367. Physician fee schedule search. Baltimore, MD: Centers for Medicare and Medicaid Services, 2014. http://www.cms.gov/apps/physician-fee-schedule. Accessed July 3, 2014
   Google Scholar
• Foley KA, Wang PF, Barber BL, et al. Clinical and economic impact of infusion reactions in patients with colorectal cancer treated with cetuximab. Ann Oncol 2010;21:1455-61
   PubMed Web of Science ®Google Scholar
• Bureau of Labor Statistics. Consumer price index - all urban consumers. Item: medical care. Washington, DC: Bureau of Labor Statistics, 2014. http://data.bls.gov. Accessed February 18, 2014
   Google Scholar
• Zafar SY, Marcello JE, Wheeler JL, et al. Treatment-related toxicity and supportive care in metastatic colorectal cancer. J Support Oncol 2010;8:15-20
   Google Scholar
• Allen RM, Goldberg RM, Berlin J, et al. Unusually high rates of hypersensitivity to cetuximab in the middle-southern United States: association with atopic phenotype. J Clin Oncol 2007;25:9051
   Google Scholar
• Kang SP, Saif MW. Infusion-related and hypersensitivity reactions of monoclonal antibodies used to treat colorectal cancer–identification, prevention, and management. J Support Oncol 2007;5:451-7
   PubMedGoogle Scholar
• Van Cutsem E, Cervantes A, Nordlinger B, et al.; Group EGW. Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-updagger. Ann Onco. 2014;25(3 Suppl):iii1-9
   Google Scholar
• Lenz H, Niedzwiecki D, Innocenti F, et al. CALGB/SWOG 80405: Phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (MFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients with expanded RAS analyses untreated metastatic adenocarcinoma of the colon or rectum (mCRC). Presented at: ESMO Congress 2014: Madrid, Spain, September 26-30, 2014
   Google Scholar
• Fragoulakis V1, Papagiannopoulou V, Kourlaba G, et al. Cost-minimization analysis of the treatment of patients with metastatic colorectal cancer in Greece. Clin Ther 2012;34:2132-42
   PubMed Web of Science ®Google Scholar